AI assistant
ABBOTT LABORATORIES — Director's Dealing 2023
Feb 23, 2023
29777_dirs_2023-02-22_3ed6e20c-f976-46d7-a8c0-d1406fd3f25d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ABBOTT LABORATORIES (ABT)
CIK: 0000001800
Period of Report: 2023-02-17
Reporting Person: Morrone Louis H. (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-02-17 | Common shares without par value | A | 10560 | — | Acquired | 57282 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-02-17 | Option (right to buy) | $106.24 | A | 41648 | Acquired | 2033-02-16 | Common Shares (41648) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common shares without par value | 2428 | Indirect |
Footnotes
F1: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.
F2: Balance in the Abbott Laboratories Stock Retirement Trust as of February 17, 2023.
F3: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 13,882 on February 17, 2024, 13,883 on February 17, 2025, and 13,883 on February 17, 2026.